Pharmacokinetic characterization of buntanetap in plasma of patients with early Alzheimer’s and Parkinson’s diseases
Analyses from two RCTs confirmed similar mean C<sub>max</sub>, T<sub>max</sub>, and AUC<sub>0-t</sub> across doses of 7.5mg-30mg buntanetap in both patients with early AD and PD. These data confirm fast plasma peak, as seen in all of our previous studies, and dose-dependent exposure to drug, supporting buntanetap's PK uniformity across AD and PD indications.
Authors
- Cheng Fang (ORCID: https://orcid.org/0000-0003-1660-4848)
- Maria L. Maccecchini (ORCID: https://orcid.org/0000-0003-1467-8675)
- Matthew J Peterson
- Alexander Morin
Institutions
- BioChem Technology (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108862
- Primary Topic
- Pharmacological Receptor Mechanisms and Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00